Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Cohort study: Among health care workers previously vaccinated with 2 doses of the Pfizer-BioNTech vaccine, receiving a third dose was associated with reduced risk of SARS-CoV-2 infection.

11 Jan, 2022 | 01:35h | UTC

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel – JAMA

Editorial: Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection – JAMA

 

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19.

11 Jan, 2022 | 01:26h | UTC

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid Advisory for Ontario

 

Commentary on Twitter

 

CDC Report: COVID-19 vaccine safety in children aged 5–11 Years.

9 Jan, 2022 | 01:09h | UTC

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021 – CDC Morbidity and Mortality Weekly Report

Commentary: COVID-19 vaccine appears safe in children aged 5–11 Years – News Medical

 

Commentary on Twitter

 

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

9 Jan, 2022 | 01:05h | UTC

Risk of myocarditis following sequential COVID-19 vaccinations by age and sex – medRxiv

Commentary: An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older – News Medical

Note: this study is an updated analysis of a recent study published in Nature Medicine; see below:

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

 

Guideline: ADA 2022 Standards of Medical Care in Diabetes.

24 Dec, 2021 | 13:38h | UTC

Guideline Homepage: ADA 2022 Standards of Medical Care in Diabetes – American Diabetes Association

Introduction: Standards of Medical Care in Diabetes—2022

Summary of Revisions: Standards of Medical Care in Diabetes—2022

Standards of Medical Care in Diabetes—2022 Guideline Abridged for Primary Care Providers

Video Summary: Standards of Care in Diabetes – 2022

  1. Improving Care and Promoting Health in Populations
  2. Classification and Diagnosis of Diabetes 
  3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities
  4. Comprehensive Medical Evaluation and Assessment of Comorbidities
  5. Facilitating Behavior Change and Well-being to Improve Health Outcomes
  6. Glycemic Targets
  7. Diabetes Technology
  8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes
  9. Pharmacologic Approaches to Glycemic Treatment
  10. Cardiovascular Disease and Risk Management
  11. Chronic Kidney Disease and Risk Management
  12. Retinopathy, Neuropathy, and Foot Care
  13. Older Adults
  14. Children and Adolescents
  15. Management of Diabetes in Pregnancy
  16. Diabetes Care in the Hospital
  17. Diabetes Advocacy

 

Commentaries on Twitter

 

AAN Guideline: Oral and topical treatment of painful diabetic polyneuropathy.

8 Jan, 2022 | 23:18h | UTC

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee – Neurology

News Release: AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy – American Academy of Neurology

 

AHA names top heart disease and stroke research advances of 2021.

8 Jan, 2022 | 23:14h | UTC

AHA names top heart disease and stroke research advances of 2021 – American Heart Association

 

FDA approves first injectable treatment for HIV pre-exposure prevention.

8 Jan, 2022 | 23:04h | UTC

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention – U.S. Food & Drug Administration

Commentaries:

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases

A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR

Related:

CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents

Study Shows High Burden of STI Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection

USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection

British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (several guidelines on the subject)

New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required

 

RCT: Long-term supplementation with marine Omega-3 fatty acids does not reduce the risk of depressive symptoms.

8 Jan, 2022 | 23:10h | UTC

Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Clinical trial reveals that omega-3 fish oil supplements do not help prevent depression – Massachusetts General Hospital

 

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

8 Jan, 2022 | 23:07h | UTC

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Easy-to-take medicine better at suppressing HIV in children – University College London

 

Commentaries on Twitter

 

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.

8 Jan, 2022 | 22:45h | UTC

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach – Nature Reviews Rheumatology (if the link is paywalled, try this one)

 

RCT: Vitamin D supplementation does not improve outcomes in people with early psychosis.

8 Jan, 2022 | 22:52h | UTC

Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis: The DFEND Randomized Clinical Trial – JAMA Network Open

 

M-A of two randomized trials: Among men with high-risk non-metastatic prostate cancer, adding abiraterone and prednisolone to standard androgen-deprivation therapy was associated with improved 6-year metastasis-free survival (82% vs. 69% in the control group).

8 Jan, 2022 | 22:42h | UTC

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol – The Lancet (link to abstract – $ for full-text)

Related Audio: Key messages of the recent report from the STAMPEDE trial platform

 

In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.

8 Jan, 2022 | 22:37h | UTC

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation – JAMA

Commentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD

Related:

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation – American Journal of Medicine

Observational Study Suggests Apixaban May Be a Better Choice than Rivaroxaban for Patients with Atrial Fibrillation

 

Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.

8 Jan, 2022 | 22:36h | UTC

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine

Commentaries:

Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist

Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology

 

RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.

17 Dec, 2021 | 09:50h | UTC

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Invited commentary: Anticoagulation in COVID-19 – The Lancet

 

Commentary on Twitter

 

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

17 Dec, 2021 | 09:52h | UTC

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)

 

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

17 Dec, 2021 | 10:01h | UTC

Interim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization

Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post

 

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

17 Dec, 2021 | 09:54h | UTC

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine

Commentaries:

Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP

Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine

Related: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (several articles on the subject)

 

CDC advisors recommend mRNA COVID vaccines over J&J.

17 Dec, 2021 | 09:46h | UTC

CDC advisors recommend mRNA COVID vaccines over J&J – CIDRAP

 

Opinion: COVID-19 vaccine strategies must focus on severe disease and global equity.

17 Dec, 2021 | 09:45h | UTC

COVID-19 vaccine strategies must focus on severe disease and global equity – The Lancet

 

How COVID vaccines shaped 2021 in eight powerful charts.

17 Dec, 2021 | 09:44h | UTC

How COVID vaccines shaped 2021 in eight powerful charts – Nature

 

Prevention of Chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes.

17 Dec, 2021 | 08:32h | UTC

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes – Drugs & Aging (if the link is paywalled, try this one)

 

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.

17 Dec, 2021 | 08:36h | UTC

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Commentary on Twitter

 

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

16 Dec, 2021 | 09:52h | UTC

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Related:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.